SPIRIVA
Total Payments
$1.4M
Transactions
35,153
Doctors
17,129
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2,484 | 105 | 62 |
| 2023 | $22,041 | 179 | 148 |
| 2022 | $47,114 | 341 | 279 |
| 2021 | $82,896 | 463 | 279 |
| 2020 | $67,339 | 564 | 434 |
| 2019 | $266,918 | 2,939 | 1,939 |
| 2018 | $371,186 | 4,453 | 2,603 |
| 2017 | $500,837 | 26,109 | 13,849 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $499,933 | 33,527 | 36.7% |
| Consulting Fee | $383,180 | 154 | 28.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $367,333 | 178 | 27.0% |
| Travel and Lodging | $103,673 | 217 | 7.6% |
| Education | $6,696 | 1,077 | 0.5% |
Top Doctors Receiving Payments for SPIRIVA — Page 686
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.4M
- Total Doctors 17,129
- Transactions 35,153
About SPIRIVA
SPIRIVA is a drug associated with $1.4M in payments to 17,129 healthcare providers, recorded across 35,153 transactions in the CMS Open Payments database. The primary manufacturer is Boehringer Ingelheim Pharmaceuticals, Inc..
Payment data is available from 2017 to 2024. In 2024, $2,484 was paid across 105 transactions to 62 doctors.
The most common payment nature for SPIRIVA is "Food and Beverage" ($499,933, 36.7% of total).